Details for Patent: 10,683,302
Which drugs does patent 10,683,302 protect, and when does it expire?
Patent 10,683,302 protects REVUFORJ and is included in one NDA.
This patent has forty-two patent family members in twenty-two countries.
Summary for Patent: 10,683,302
| Title: | Inhibitors of the menin-MLL interaction |
| Abstract: | The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction. |
| Inventor(s): | Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel MORALES-RAMOS, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun ZHENG, Linghang Zhuang, Stephan D. PARENT, Travis L. Houston |
| Assignee: | Vitae Pharmaceuticals LLC |
| Application Number: | US16/308,739 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 10,683,302
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Syndax | REVUFORJ | revumenib citrate | TABLET;ORAL | 218944-001 | Nov 15, 2024 | RX | Yes | No | 10,683,302 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Syndax | REVUFORJ | revumenib citrate | TABLET;ORAL | 218944-002 | Nov 15, 2024 | RX | Yes | No | 10,683,302 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Syndax | REVUFORJ | revumenib citrate | TABLET;ORAL | 218944-003 | Nov 15, 2024 | RX | Yes | Yes | 10,683,302 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,683,302
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017278950 | ⤷ Start Trial | |||
| Australia | 2021258089 | ⤷ Start Trial | |||
| Australia | 2024202700 | ⤷ Start Trial | |||
| Brazil | 112018075260 | ⤷ Start Trial | |||
| Brazil | 122024002146 | ⤷ Start Trial | |||
| Canada | 3024180 | ⤷ Start Trial | |||
| Canada | 3297462 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
